Metabolic dysfunction associated steatotic liver disease(MASLD)is associated with metabolic dysfunction such as insulin resistance and has become the most common liver disease worldwide.In the past 40 years,no drug has been approved by the USA FDA,but the recent approval of Rezdiffra has marked a significant break through in this field.The pathogenesis of MASLD is complex,including disorders of glucose and lipid metabolism,insulin resistance,inflammation,intestinal flora,genetic predisposition,etc.The pathogenesis of MASLD is also complex,including disorders of glucose and lipid metabolism,insulin resistance,inflammation,intestinal flora,and genetic predisposition.Glucagon-like peptide-1(GLP-1)drugs are primarily used in the treatment of diabetes mellitus,however a large number of studies have proved that GLP-1 receptor agonists(GLP-1 RA)can promote fatty acid oxidation,improve insulin resistance,and inhibit inflammation,and therefore they also have great potential for the treatment of MASLD.This article summarizes the pathogenesis of MASLD,the mechanism of GLP-1RA in improving MASLD,and the recent progress in drug research.
维普
万方数据